Cooley Honored With Three China Business Law Awards
Beijing, Hong Kong and Shanghai – June 21, 2022 – For the fourth consecutive year, the China Business Law Journal has honored Cooley as part of its China Business Law Awards 2022. The firm is one of only eight international law firms recognized with awards in the private equity & venture capital, healthcare, pharma & life sciences, and asset management categories.
The China Business Law Awards are based on direct feedback and thousands of votes and recommendations received from in-house counsel, other senior corporate executives, and legal professionals from around the world. In determining the winners, the China Business Law Journal also considers each firm’s significant transactions, cases or other notable achievements from the past year.
The publication highlighted praise for Cooley in each of the three categories in which the firm took home an award, saying, “Cooley focuses on US dollar venture capital fund formation in the Asia market, with its practice supported closely by the Beijing, Shanghai, Hong Kong, Singapore and San Francisco offices. The firm is currently representing more than 100 Asia-based VC fund managers, including top-tier firms, ‘new generation’ VC managers and corporate-backed VC firms.”
Of the firm’s VC and private equity work, the publication notes, “Cooley’s VC/PE practice in China keeps growing significantly, a balanced representation of both company-side and investor-side clients, especially in the areas of life sciences, fintech, new consumer, edtech, SaaS, big data, AI, insurtech, online retail and other high-technology sectors.”
Among all international law firms practicing in China, Cooley has the largest China-based offshore fund formation team, and represents the deepest experience and greatest reach and depth for China VC fund formation – especially venture firms focusing on early and growth stages.
With offices in Beijing, Hong Kong and Shanghai, Cooley represents a growing number of China’s most innovative and dynamic tech and life sciences companies, advising at all stages of their life cycle, from formation through financings and exits. The team’s in-depth subject matter knowledge and transactional prowess enable the firm to handle a raft of corporate, finance, M&A, and capital markets work for international and China-based high-tech and life sciences entities engaged in inbound and outbound endeavors.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,500 lawyers across 17 offices in the United States, Asia and Europe.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.